Continue Reading With Our 7-Day Free Trial
Hims & Hers Health (NYSE:HIMS) did not report a surprise quarter, launch a blockbuster product, or raise guidance when the stock jumped after Robert F. Kennedy Jr.’s peptide announcement. That is what makes the move interesting.
The market was not reacting to a near-term earnings change. It was reacting to the possibility that the company could regain something more important: control. For the last year, much of the debate around Hims has centered on GLP-1s, compounding, and whether the company could keep its momentum as rules changed.
But the latest policy shift points to a broader story. If peptides move back toward a clearer compounding pathway, Hims may be able to reopen a category with better economics, tighter supply control, and more room for customization. That does not mean revenue arrives tomorrow. It does mean investors suddenly have a new reason to look at the business through the lens of margin structure, not just headline growth.
Regulation Shifted The Margin Story
The market’s first reaction looked dramatic, but the logic behind it was fairly simple. A regulatory rollback can change economics long before it changes reported revenue.
In this case, the policy move reopened the possibility that certain peptides could return to a more legitimate compounding path after being boxed out by the 2023 classification. That matters because Hims has already built a business around direct consumer access, personalized treatment workflows, and non-traditional pharmacy models.
When those categories are constrained, Hims leans more heavily on branded distribution and loses some pricing flexibility. When those categories open up, the company gets back a larger degree of economic control.
That is why the rally looked like a re-rating rather than a response to immediate fundamentals. The FDA review is still ongoing, and management has not suggested an overnight revenue windfall.
Yet investors do not need current sales to change in order to rethink future margins. If peptides become more accessible through compliant compounding channels, Hims could serve demand with a better mix, stronger gross profit potential, and a more flexible operating model.
In that sense, the stock did not jump because the numbers changed. It jumped because the market started to imagine a business with a better shape. That is often how revaluations begin.
The Infrastructure Was Built Before The Headline
One reason this angle carries weight is that Hims did not need to invent a new strategy after the announcement. The company had already spent heavily to prepare for a more vertical model.
Management said it invested more than $300 million over the last three years into facilities, pharmacy operations, lab capabilities, and R&D tied to personalized care, including peptide therapies. It also said its footprint now exceeds one million square feet.
That is not the language of a company running experiments. It is the language of a company laying track for scale. The peptide headline therefore mattered less as a green light for a new idea and more as validation for spending that had already happened.
That distinction is important. Investors are not just pricing a future opportunity. They are also pricing the possibility that prior capital allocation now looks strategically correct.
The manufacturing facility acquisition starts to look less like optional expansion and more like pre-positioning. That changes the tone of the investment case. Instead of asking whether Hims can build the tools, the better question becomes whether regulation will let the company use what it already built.
Peptides Could Restore Strategic Control After Novo
The Novo Nordisk agreement helped stabilize one part of the GLP-1 story, but it also changed the economics. Hims moved toward selling branded therapies, which reduces flexibility.
Branded distribution can bring volume and trust, but it limits margin expansion and customization. That creates a gap. Peptides reopen a different path.
They allow Hims to move back toward categories where it has more influence over formulation, manufacturing, and delivery. That is not a small shift. It directly impacts how the company captures value per user.
Management has also emphasized that GLP-1s are not the core business. Most revenue comes from non-GLP-1 categories, and only a small share of users rely on compounded GLP-1 treatments.
This reframes the narrative. Peptides are not just a replacement. They act as both defense and offense.
They offset lost economics while opening a broader category tied to performance, recovery, and longevity.
The Real Opportunity Is Bigger Than One Product
The most interesting part of the story may not be any single therapy. It may be the system Hims is building.
Management described a platform connecting labs, AI, diagnostics, and treatment pathways into a single loop. More than 70% of lab users identify a treatable condition on the platform.
That creates a powerful cycle. Data leads to diagnosis. Diagnosis leads to treatment. Treatment drives retention.
This turns the platform into a conversion engine for healthcare demand. Peptides fit directly into this system.
They expand the set of treatments that can be delivered within that loop. At the same time, personalized treatments already drive engagement. About 65% of subscribers use personalized solutions.
That signals where the model is going. Not just telehealth, but a high-retention, high-LTV healthcare platform built on data and personalization.
Final Thoughts
The market appears to be treating Hims as a company with more strategic optionality than before. That does not mean certainty.
The FDA process is still evolving, and the company remains in an investment-heavy phase. At the same time, valuation reflects a shift in expectations.
On a trailing basis, Hims trades around 2.85x EV/Revenue, 3.86x EV/Gross Profit, 38.11x EV/EBITDA, and 52.69x P/E. These multiples are not distressed, but they are not extreme if investors believe in margin expansion over time.
The key question is no longer growth alone. It is whether the company can translate regulatory tailwinds and existing infrastructure into durable economics.
Disclaimer: We do not hold any positions in the above stock(s). Read our full disclaimer here.
